retatrutide weight loss results Lilly's triple agonist, retatrutide, delivered powerful in pivotal Phase 3 obesity trial Retatrutide vs. Other Weight Loss

With data from this trial in hand, Lilly said, it now has the full clinical package needed to start filing for approvals of orforglipron with various regulators

Aggregated review data across major platforms shows a pattern worth understanding

Pancreatic alpha-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist it activates all three receptors simultaneously

GLP-1 (glucagon-like peptide-1) receptor agonists, such as semaglutide and liraglutide, were originally developed to treat type 2 diabetes but have also shown strong effectiveness in managing obesity and supporting weight loss

International Diabetes Federation (2017) The IDF Consensus Statement on sleep apnoea and type 2 diabetes